LOTTE Biologics Songdo Plant 1 Lands First Major Commercial Manufacturing Agreement Ahead of Launch

LOTTE Biologics Songdo Plant 1 has secured its first major commercial manufacturing commitment before the facility has begun operations, according to a November 17, 2026 announcement from the contract development and manufacturing organization. LOTTE Biologics, led by Co-CEOs James Park and Yoo-yeol Shin, said it signed the agreement with a global pharmaceutical company. The company describes the deal as a significant milestone in the commercialization of its Songdo Bio Campus in South Korea.

Under the partnership, LOTTE Biologics will provide integrated drug substance and drug product manufacturing services for key products in the customer’s portfolio. Commercial production is targeted to begin in 2027. The announcement did not name the customer, the products, the contract value or the committed volumes, so those details are listed as Not disclosed in this report. Timelines described here are the company’s stated targets, not guaranteed outcomes.

The agreement is the first major commercial manufacturing commitment tied to LOTTE Biologics Songdo Plant 1, and it was secured ahead of the plant’s operational launch. Commitments made while a site is still under development can show how pharmaceutical sponsors weigh a new CDMO’s technical credentials and supply reliability.

Early Commercial Success for LOTTE Biologics Songdo Plant 1 Validates Growth Strategy

LOTTE Biologics framed the early commitment as validation of its growth strategy. The company says that securing commercial manufacturing volume while the facility is still under development shows customer confidence in its technical expertise, execution capabilities and long-term supply reliability. It adds that it is aligning capacity expansion with customer commitments from the outset, which it says accelerates its path to commercialization and builds a foundation for sustainable growth.

Co-CEO James Park called the agreement “a strong endorsement of our strategy.” He added that the company is not simply building manufacturing capacity but a globally integrated platform designed to deliver quality, reliability and speed. He said that combining the expertise of its Syracuse site with the infrastructure at Songdo positions LOTTE Biologics to support its partners and bring medicines to patients worldwide.

Advertisement

These statements are company assertions made in a press announcement. The release contains no independent customer commentary, financial terms or named counterparty. This article therefore treats the commercial significance of LOTTE Biologics Songdo Plant 1 as an early indicator, not a confirmed revenue forecast.

LOTTE Biologics Songdo Plant 1 Infrastructure: Capacity and Cold-Chain Design

According to the company, the facility is designed to meet the evolving demands of global biopharmaceutical manufacturing. LOTTE Biologics Songdo Plant 1 features state-of-the-art production infrastructure, advanced automation and large-scale cold-chain warehousing. The company says these are intended to support efficient, reliable and quality-driven operations.

The Songdo Bio Campus is being developed with a planned capacity of 360,000 liters across three plants. Within that plan, Plant 1 provides 120,000 liters through eight 15,000-liter stainless-steel bioreactors. Eight bioreactors of 15,000 liters each equal 120,000 liters, or one-third of the campus’s planned total. The company did not publish capacity figures or a construction timeline for the second and third plants in this announcement.

These figures let sponsors and analysts size the site against the campus-wide plan. The 360,000-liter target spans three plants, and Plant 1 is the one now linked to a major commercial commitment, even though the customer is unnamed. Readers can find broader context in our biologics capacity expansion coverage.

Cold-chain warehousing and automation are named as core design features, but the company did not provide technical specifications for either. Detailed engineering data on LOTTE Biologics Songdo Plant 1, including automation platforms and warehouse footprint, is therefore Not disclosed.

Advertisement

Syracuse Bio Campus Pairs With LOTTE Biologics Songdo Plant 1 as an Integrated Network

The Songdo site will complement the established Syracuse Bio Campus in New York. LOTTE Biologics says Syracuse brings more than two decades of manufacturing experience, a track record supporting over 62 regulatory approvals, and a recent FDA inspection completed with zero observations. The company points to these credentials when positioning its new Korean facility.

Together, the two sites form what the company calls an integrated global manufacturing network. It is designed to deliver operational flexibility, consistent quality standards and greater supply chain resilience. A footprint linking New York and Incheon, with LOTTE Biologics Songdo Plant 1 as the newest site, is presented as a way for sponsors to diversify supply geography. The announcement does not specify which site will supply which customer product.

The zero-observation FDA inspection outcome refers to the Syracuse site, not to Songdo, which has not yet launched operations. Readers evaluating regulatory readiness should keep Syracuse’s inspection history separate from the future qualification path of LOTTE Biologics Songdo Plant 1, which the company did not describe in this release. For background on inspection frameworks, see the U.S. Food and Drug Administration.

Agreement Snapshot

AttributeDetail
Announcement dateNovember 17, 2026
DatelineSeoul, South Korea
Announcing companyLOTTE Biologics
Co-CEOsJames Park and Yoo-yeol Shin
CounterpartyA global pharmaceutical company (name not disclosed)
ServicesIntegrated drug substance and drug product manufacturing
Commercial production target2027 (forward-looking)
FacilitySongdo Plant 1, Songdo Bio Campus
Contract valueNot disclosed

Songdo Bio Campus Capacity

MetricValue
Planned campus capacity360,000 liters
Number of planned plants3
Plant 1 capacity120,000 liters
Plant 1 bioreactors8
Bioreactor size15,000 liters each
Bioreactor typeStainless steel
Other Plant 1 featuresAdvanced automation; large-scale cold-chain warehousing
Plant 2 and Plant 3 capacityNot disclosed

Related Leads